Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

Adopting target saturations 88%–92% for all hospitalised patients with COPD would simplify clinical pathways and should improve outcomes ... Guidelines from the BTS and endorsed by the ERS state that ...

27 Patient demographics captured age; sex; SES (IMD1 (least deprived) to IMD5 (most deprived23)) and comorbidities, including anxiety, atopy, chronic obstructive pulmonary disease (COPD), gastro ...

The aim of this study is to develop an a priori protocol to broadly review the available evidence on the use of drugs targeting the JAK/STAT pathway in the treatment of dermatological diseases.

In patients with COPD, too much mucus can increase the number of flare-ups, when symptoms increase. It may also increase the risk of respiratory-related death. The goal of treatment is to help you ...

“In the current treatment landscape for patients experiencing an acute exacerbation with asthma or COPD, there are no approved biologics that can rapidly improve lung function and prevent ...

In severe cases, the disease can lead to reduced airflow and premature death, making it imperative to enhance treatment availability and efficacy. In the United States alone, over two million ...

"In the current treatment landscape for patients experiencing an acute exacerbation with asthma or COPD, there are no approved biologics that can rapidly improve lung function and prevent further ...

Researchers hope their findings, published in Lancet Psychiatry, could provide a new treatment pathway for people with depression who have not benefitted from previous treatment. The study was led ...